Dupilumab Linked to Early Symptom Relief in Atopic Dermatitis

Key Takeaways

• Among adults with atopic dermatitis receiving dupilumab in TREATgermany, greater baseline depressive symptoms or fatigue coincided with worse dermatology-related quality of life despite similar objective skin severity.
• Depressive symptoms and fatigue declined markedly early in dupilumab treatment.
• Sleep and social-functioning needs were more common initially in higher-burden groups and were more often fulfilled after 12 months.
• Drug survival was comparable across groups defined by baseline depressive symptoms or fatigue.

Depressive symptoms and fatigue can accompany adult atopic dermatitis, adding dimensions of burden that may not be apparent from skin examination alone. During routine dupilumab treatment, how do patient-reported concerns relate to objective skin scores over time? Investigators tracked both types of measures in adults receiving dupilumab through the TREATgermany registry.

In this longitudinal cohort analysis of 633 adults with atopic dermatitis, elevated baseline depressive symptoms were defined as a Center for Epidemiologic Studies Depression Scale (CES-D) score ≥16, and significant fatigue as a Fatigue Severity Scale (FSS) score >4. These were separate grouping criteria, not treatment arms. Assessments included the Eczema Area and Severity Index (EASI), objective Scoring Atopic Dermatitis (oSCORAD), and Dermatology Life Quality Index (DLQI), alongside CES-D and FSS scores, patient treatment needs and benefits, and drug survival.

At baseline, 309 adults met the elevated depressive-symptom criterion and 281 met the significant-fatigue criterion. Adults in either elevated-score group reported worse dermatology-related quality of life on the DLQI, while EASI and oSCORAD scores did not differ between the corresponding baseline burden groups.

CES-D and FSS scores decreased markedly within the first 3 months of dupilumab treatment; during treatment, improvements in depressive symptoms, fatigue, and skin severity were reported as significant. Adults in the higher-burden groups more often reported needs involving sleep and social functioning initially, and those reported needs were more often fulfilled after 12 months. Fulfillment of a reported need is distinct from a quantified change in sleep or social function. Drug survival was comparable across groups defined by baseline depressive symptoms or fatigue.

Objective skin severity scores alone may not reflect the full patient-reported burden in this German registry cohort. These longitudinal observations describe associations during dupilumab treatment rather than establishing a causal mental-health effect.

The authors concluded that adults with greater baseline mental-health burden experienced improvements in patient-relevant domains during dupilumab treatment for atopic dermatitis.

Clinician Questions

Which measures assessed treatment needs and benefits among adults with atopic dermatitis receiving dupilumab?

PNQ and PBI were used to assess patient treatment needs and benefits in the TREATgermany cohort.

Do the high-depression and high-fatigue groups in TREATgermany represent separate patients with atopic dermatitis?

The baseline depressive-symptom and fatigue groups were defined separately; their counts cannot be treated as representing mutually exclusive patients.

Recommended Reading

• For more on symptom burden in AD: Add-On Antihistamines Offer Little Benefit in Atopic Dermatitis
• For more on QoL-driven escalation in AD: Treating Atopic Dermatitis in Sensitive and High-Impact Areas